Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR52 | Q9Y2T5 | 3/20 | 0.52 |
| ▸ | PARP1 | P09874 | 2/20 | 0.44 |
| ▸ | SLC9A1 | P19634 | 8/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.39 |
| ▸ | PRKCI | P41743 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1851699 | 0.90 | GPR52 (0.52) | GPR52SLC9A1S1PR5PLA2G2AS1PR4 | |
| SCHEMBL3209979 | 0.87 | GPR52 (0.61) | GPR52SLC9A1S1PR5S1PR4 | |
| SCHEMBL7955979 | 0.85 | GPR52 (0.51) | GPR52SLC9A1S1PR5S1PR4 | |
| SCHEMBL3204287 | 0.85 | GPR52 (0.50) | GPR52S1PR5NPC1RAB9A | |
| SCHEMBL1852510 | 0.84 | GPR52 (0.57) | GPR52SLC9A1S1PR5PLA2G2AS1PR4 | |
| SCHEMBL1852511 | 0.84 | GPR52 (0.44) | GPR52PARP1SLC9A1S1PR5S1PR4 | |
| SCHEMBL1856035 | 0.81 | GPR52 (0.49) | GPR52S1PR5NPC1RAB9A | |
| SCHEMBL3219164 | 0.81 | GPR52 (0.52) | GPR52PARP1NPC1RAB9APLA2G2A | |
| SCHEMBL1851289 | 0.81 | GPR52 (0.50) | GPR52SLC9A1S1PR5PLA2G2AS1PR4 | |
| SCHEMBL3204361 | 0.81 | GPR52 (0.59) | GPR52S1PR5S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | GPR52, GPR132, NR5A2 | GPR52 1/4885PARP1 2217/4885SLC9A1 1722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.